Amphastar Pharmaceuticals (FRA:29A) EV-to-Revenue : 3.49 (As of May. 15, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Amphastar Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Amphastar Pharmaceuticals's enterprise value is €2,184.0 Mil. Amphastar Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €625.1 Mil. Therefore, Amphastar Pharmaceuticals's EV-to-Revenue for today is 3.49.

The historical rank and industry rank for Amphastar Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

FRA:29A' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.63 Med: 3.02 Max: 6.84
Current: 3.48

During the past 13 years, the highest EV-to-Revenue of Amphastar Pharmaceuticals was 6.84. The lowest was 1.63. And the median was 3.02.

FRA:29A's EV-to-Revenue is ranked worse than
65.98% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.375 vs FRA:29A: 3.48

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-15), Amphastar Pharmaceuticals's stock price is €38.80. Amphastar Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €11.73. Therefore, Amphastar Pharmaceuticals's PS Ratio for today is 3.31.

Amphastar Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Amphastar Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals EV-to-Revenue Chart

Amphastar Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

2.87

2.75

2.47

2.56

5.18

Amphastar Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															3.31	5.86	4.28	5.18	3.67

Competitive Comparison of Amphastar Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amphastar Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's EV-to-Revenue falls into.

Amphastar Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Amphastar Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2184.017	/	625.084
	=	3.49

Amphastar Pharmaceuticals's current Enterprise Value is €2,184.0 Mil.
Amphastar Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €625.1 Mil.

Amphastar Pharmaceuticals (FRA:29A) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Amphastar Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	38.80	/	11.734
	=	3.31

Amphastar Pharmaceuticals's share price for today is €38.80.
Amphastar Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.73.

Amphastar Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Amphastar Pharmaceuticals (FRA:29A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (FRA:29A) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

AMPH:USA 29A:Germany

Address

11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website

http://www.amphastar.com

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Amphastar Pharmaceuticals (FRA:29A) Headlines

No Headlines